Tablets Capsules

TC0321

Issue link: https://www.e-digitaleditions.com/i/1349974

Contents of this Issue

Navigation

Page 9 of 59

8 March/April 2021 Tablets & Capsules research Researchers develop stabilized form of osteoporosis treatment WEST LAFAYETTE, IN—Research- ers at Purdue University have developed a stabilized form of human calcitonin, a peptide hormone, to increase its effec- tiveness as an osteoporosis treatment. Calcitonin is the hormone responsi- ble for normal calcium homeostasis. When taken by osteoporosis patients, it inhibits bone resorption, resulting in increased bone mass. However, calcitonin undergoes fibrillation in aqueous solution, leading to reduced efficacy when used as a therapeutic. To decrease the fibrillation propensity and increase the therapeutic benefit of human calcitonin, Purdue researchers phosphorylated specific amino acid residues. The study was published in Biophysical Journal. Goldenseal decreases absorption of metformin in diabetes patients SPOKANE, WA—A clinical study led by scientists at Washington State University's College of Pharmacy and Pharmaceutical Sciences suggests that goldenseal, a perennial herb native to North America, alters the absorption of metformin, the most prescribed oral glucose-lowering medication, leading to unstable glucose levels in diabetic patients taking metformin. Goldenseal is a popular natural herbal remedy used to self-treat the common cold, respiratory tract infections, digestive issues, rashes, and other skin problems. The goal of the study was to determine the impact of goldenseal on proteins that facilitate absorption or expulsion of drug mole- cules in the intestine, liver, kidney, and other tissues. According to the study published in the journal Clinical Pharma- cology & Therapeutics, six days after taking the herbal remedy along with a cocktail of other selected drugs, participants had about 25 percent less metformin in their bodies. Unstable glucose levels can increase a patient's risk of heart disease, kidney disease, and infections. markets Effervescent tablet market to exceed $46 billion by 2027 PUNE, India—The global effer- vescent tablet market is forecast to grow at a compound annual rate of 8.3 percent through 2027, reaching $46.93 billion, according to a report by Data Bridge Market Research. The North American sector is expected to expand the quickest during the forecast period due to an upsurge in demand for functional drugs in that market. The report identifies Bayer, GSK, Prestige Brands, Nuun and Company, DMK, Herbalife, Reck- bitt Bencksier, Nomax, Bristol-Myers Squibb, Hermes Arzneimittel, Pyramid Pharmaceuticals, Tower Laboratories, US Pharma Lab, Nutrilo, JW Nutri- tional, Paragon Labs, and Amerilab Technologies as major market players. Pharmaceutical excipients market to grow 5 percent annually through 2027 ALBANY, NY—The global pharma- ceutical excipients market is projected to reach $10.7 billion by the end of 2027, growing at a compound annual rate of about 5 percent, according to a report from Transparency Market Research. Increasing FDA approval of oral solid dosage formulations due to high patient preference for oral med- ications is expected to drive market growth. Key market players include BASF, Colorcon, Ashland, Croda Inter- national, Roquette, Evonik, DuPont, Associated British Foods, Archer Dan- iels Midland, and Lubrizol. Prevalence of adverse drug reactions to drive pharmacovigilance market growth SAN FRANCISCO, CA—The global pharmacovigilance market is forecast to reach $14.95 billion by 2028, growing at a compound annual rate of 11.5 percent according to a report by Grand View Research. A key factor driving market growth is the increasing incidence of adverse drug reactions. Manufacturers focusing on remodeling their product development processes to cater to patient needs worldwide is also anticipated to fuel demand for pharmacovigilance ser- vices during the forecast period. Key market players include Accenture, Lin- ical, Accelovance, IQVIA, Cognizant, Laboratory Corporation of America, IBM, ArisGlobal, Icon, Capgemini, ITClinical, Take Solutions, Parexel International, BioClinica, Wipro, United Biosource, and FMD K&L. Latin America pharmaceutical products CMO market to grow 14.7 percent annually S E A T T L E , W A — T h e L a t i n America pharmaceutical products CMO market is forecast to grow at a compound annual rate 14.7 percent through 2027, according to a report by Coherent Market Insights. The increase in mergers and acquisitions among Latin American pharmaceu- tical CMOs and the prevalence of chronic disorders are expected to drive growth during the forecast period. The pharmaceutical packaging seg- ment is expected to hold a major market revenue share in 2027. Key market players identified by the report include BASF, Bayer, Boehringer Ingel- heim, F. Hoffmann-La Roche, Merck, Novartis, Pfizer, Pisa Farmacéutica, Fresenius, Takeda Pharmaceutical, Fer- ring Pharmaceuticals, and Landsteiner Scientific. industry news FDA expands Entresto indications to include heart failure SILVER SPRING, MD—The FDA approved an extended indication for Entresto (sacubitril/valsartan), making it the first and only approved therapy in the US to treat adult patients diag- nosed with heart failure. This includes patients suffering from heart failure with reduced ejection fraction and heart fail- ure with preserved ejection fraction. The approval of this expanded indi- cation will also enable the potential treatment of more adults with left ven- tricular ejection fraction below normal. Entresto is manufactured by Novartis, East Hanover, NJ.

Articles in this issue

Archives of this issue

view archives of Tablets Capsules - TC0321